Platinum Based Cancer Drug Market Overview
Chemotherapy can reduce a tumour enough for added treatments like radiation and surgery to be thought of. this is often said as neoadjuvant medical care by doctors. to reduce the severity of signs and symptoms. chemotherapy might assist to alleviate cancer symptoms by killing some cancer cells. Platinum-based compounds square measure key cancer chemotherapeutical medicines or medication prospects. as a result of a platinum atom is connected 2|to 2} ammonion molecules and two chloride ions, platinum-based medications are effective against cancer. The chemical is charged, however once it enters a neoplastic cell, the chloride ions are replaced by water molecules, and it becomes charged. ancient platinum medicines, like cisplatin, carboplatin, and oxaliplatin, square measure neutral platinum (II) complexes containing 2 amine ligands and 2 further ligands that may be aquated for hyperbolic desoxyribonucleic acid binding. Platinum-DNA adducts will hinder cellular processes and cause cell death.
Resistance to platinum medicines in tumours has become a tough drawback to resolve. personal cancer treatment that employs a range of the way to beat platinum-drug resistance in cancer patients is essential. ancient platinum drug structural alteration, platinum drug combination medical care with further agents, and increased platinum drug transport to tumour locations are a number of the key methods established to deal with difficulties with ancient platinum drug therapy.
| Report Metric |
Details |
| Market size available for years |
2023–2030 |
| Base year considered |
2023 |
| Forecast period |
2024–2030 |
| Forecast unit |
Value (USD Million) |
| Segments covered |
Type, Distribution Channel, and Region |
| Regions covered |
North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA) |
| Companies covered |
Accord Healthcare, Novartis, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Jiangsu Hengrui Pharmaceutical Co., Ltd, Debiopharm Group, Pfizer, Inc., Mylan N.V, Sanofi and Bristol-Myers Squibb Company |
The covid-19 Impact on Platinum Based Cancer Drug Market:
Whereas, the chemicals and accouterments sectors were relatively affected during the pandemic. This is primarily due to uncut demand for chemicals for healthcare, life wisdom, and drawing agents. However, other elements of chemical and material sectors such as types of paints, industrial oil, construction materials are facing reduction in demand. Strict lockdown reflected in a nearly 50-60% reduction in force for raw supply and availability, which directly affected the manufacturing process. Further, halt on numerous end-use diligence directly affected the chemical demand each around the world.
Platinum Based Cancer Drug market Segment Overview
By Type, Cisplatin product segment accounted for the largest industry share in 2018 and can witness notable growth through 2026
By Applications, lung cancer application segment captured a considerable share of the market in 2018 and can seemingly drive a substantial product demand considerably. this could be attributed to the upper occurrence of pulmonary cancers among the worldwide population.
Market Analysis, Insights and Forecast – By Type
· Cisplatin
· Oxaliplatin
· Carboplatin
· Others
Market Analysis, Insights and Forecast – By Application
· Colorectal Cancer
· Ovarian Cancer
· Lung Cancer
· Others
Platinum Based Cancer Drug Market Regional Overview
Region-wise, in terms of regions ,Due to enhanced disease prevalence, increased awareness, enlarged per capita income, and increased health care infrastructure, the Asia Pacific market is anticipated to develop at the most important CAGR. North America dominated the world market in 2018 due to the high incidence of cancer within the region, developments in these medicine and recent Food and Drug Administration approvals. us is that the world’s largest drug market. This has led to the dominance of North America within the global platinum cancer drug market. The U.S. pharmaceutical trade is that the largest domestic market within the world. it's the world’s biggest continental pharmaceutical market in conjunction with North American nation and Mexico.
Platinum Based Cancer Drug Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Platinum Based Cancer Drug Market Competitor overview
Some key developments and strategies adopted by manufacturers in the Platinum Based Cancer Drug are highlighted below.
· In 2021, Pfizer Inc. and therapeutics medical specialty therapeutics. had a definitive agreement consistent with that Pfizer acquired trillium, a clinical-stage immune-oncology business researching novel cancer medicines.
Platinum Based Cancer Drug Market, Key Players -
· Accord Healthcare,
· Novartis,
· Sun Pharmaceutical Industries Ltd.,
· Dr. Reddy’s Laboratories Ltd.,
· Jiangsu Hengrui Pharmaceutical Co., Ltd,
· Debiopharm Group,
· Pfizer, Inc.,
· Mylan N.V,
· Sanofi
· Bristol-Myers Squibb Company.
Frequently Asked Questions (FAQ) :
Q1. What is the total CAGR expected to be recorded for the Platinum Based Cancer Drug Market during the forecast period?
Platinum Based Cancer Drug market is expected to record a CAGR of ~ XX % during the forecast period
Q2. Which segment is projected to hold the largest share in the Platinum Based Cancer Drug Market?
Lung cancer segment is projected to hold the largest share in the Platinum Based Cancer Drug Market
Q3. What are the driving factors for the Platinum Based Cancer Drug Market?
The increase in prevalence disease , enhanced awareness, increased per capita income, and enhanced health care infrastructural, the growing variety of pipeline studies , these are main factors driving the growth of automotive lighting market
Q4. Which Segments are covered in the Platinum Based Cancer Drug Market report?
Type, Application and Region, these segments are covered in the Platinum Based Cancer Drug Market report.
Q5. Which are the prominent players offering Platinum Based Cancer Drug Market?
Accord Healthcare, Novartis, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Jiangsu Hengrui Pharmaceutical Co., Ltd, Debiopharm Group, Pfizer, Inc., Mylan N.V, Sanofi and Bristol-Myers Squibb Company
List of Figures
Figure 1: Global Platinum based Cancer Drug Market Revenue Breakdown (USD Billion, %) by Region, 2019 & 2027
Figure 2: Global Platinum based Cancer Drug Market Value Share (%), By Segment 1, 2019 & 2027
Figure 3: Global Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 4: Global Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 5: Global Platinum based Cancer Drug Market Value Share (%), By Segment 2, 2019 & 2027
Figure 6: Global Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 7: Global Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 8: Global Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 9: Global Platinum based Cancer Drug Market Forecast (USD Billion), by Others, 2016-2027
Figure 10: Global Platinum based Cancer Drug Market Value Share (%), By Segment 3, 2019 & 2027
Figure 11: Global Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 12: Global Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 13: Global Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 14: Global Platinum based Cancer Drug Market Forecast (USD Billion), by Others, 2016-2027
Figure 15: Global Platinum based Cancer Drug Market Value (USD Billion), by Region, 2019 & 2027
Figure 16: North America Platinum based Cancer Drug Market Value Share (%), By Segment 1, 2019 & 2027
Figure 17: North America Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 18: North America Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 19: North America Platinum based Cancer Drug Market Value Share (%), By Segment 2, 2019 & 2027
Figure 20: North America Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 21: North America Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 22: North America Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 23: North America Platinum based Cancer Drug Market Forecast (USD Billion), by Others, 2016-2027
Figure 24: North America Platinum based Cancer Drug Market Value Share (%), By Segment 3, 2019 & 2027
Figure 25: North America Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 26: North America Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 27: North America Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 28: North America Platinum based Cancer Drug Market Forecast (USD Billion), by Others, 2016-2027
Figure 29: North America Platinum based Cancer Drug Market Forecast (USD Billion), by U.S., 2016-2027
Figure 30: North America Platinum based Cancer Drug Market Forecast (USD Billion), by Canada, 2016-2027
Figure 31: Latin America Platinum based Cancer Drug Market Value Share (%), By Segment 1, 2019 & 2027
Figure 32: Latin America Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 33: Latin America Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 34: Latin America Platinum based Cancer Drug Market Value Share (%), By Segment 2, 2019 & 2027
Figure 35: Latin America Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 36: Latin America Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 37: Latin America Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 38: Latin America Platinum based Cancer Drug Market Forecast (USD Billion), by Others, 2016-2027
Figure 39: Latin America Platinum based Cancer Drug Market Value Share (%), By Segment 3, 2019 & 2027
Figure 40: Latin America Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 41: Latin America Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 42: Latin America Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 43: Latin America Platinum based Cancer Drug Market Forecast (USD Billion), by Others, 2016-2027
Figure 44: Latin America Platinum based Cancer Drug Market Forecast (USD Billion), by Brazil, 2016-2027
Figure 45: Latin America Platinum based Cancer Drug Market Forecast (USD Billion), by Mexico, 2016-2027
Figure 46: Latin America Platinum based Cancer Drug Market Forecast (USD Billion), by Rest of Latin America, 2016-2027
Figure 47: Europe Platinum based Cancer Drug Market Value Share (%), By Segment 1, 2019 & 2027
Figure 48: Europe Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 49: Europe Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 50: Europe Platinum based Cancer Drug Market Value Share (%), By Segment 2, 2019 & 2027
Figure 51: Europe Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 52: Europe Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 53: Europe Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 54: Europe Platinum based Cancer Drug Market Forecast (USD Billion), by Others, 2016-2027
Figure 55: Europe Platinum based Cancer Drug Market Value Share (%), By Segment 3, 2019 & 2027
Figure 56: Europe Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 57: Europe Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 58: Europe Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 59: Europe Platinum based Cancer Drug Market Forecast (USD Billion), by Others, 2016-2027
Figure 60: Europe Platinum based Cancer Drug Market Forecast (USD Billion), by U.K., 2016-2027
Figure 61: Europe Platinum based Cancer Drug Market Forecast (USD Billion), by Germany, 2016-2027
Figure 62: Europe Platinum based Cancer Drug Market Forecast (USD Billion), by France, 2016-2027
Figure 63: Europe Platinum based Cancer Drug Market Forecast (USD Billion), by Italy, 2016-2027
Figure 64: Europe Platinum based Cancer Drug Market Forecast (USD Billion), by Spain, 2016-2027
Figure 65: Europe Platinum based Cancer Drug Market Forecast (USD Billion), by Russia, 2016-2027
Figure 66: Europe Platinum based Cancer Drug Market Forecast (USD Billion), by Rest of Europe, 2016-2027
Figure 67: Asia Pacific Platinum based Cancer Drug Market Value Share (%), By Segment 1, 2019 & 2027
Figure 68: Asia Pacific Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 69: Asia Pacific Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 70: Asia Pacific Platinum based Cancer Drug Market Value Share (%), By Segment 2, 2019 & 2027
Figure 71: Asia Pacific Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 72: Asia Pacific Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 73: Asia Pacific Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 74: Asia Pacific Platinum based Cancer Drug Market Forecast (USD Billion), by Others, 2016-2027
Figure 75: Asia Pacific Platinum based Cancer Drug Market Value Share (%), By Segment 3, 2019 & 2027
Figure 76: Asia Pacific Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 77: Asia Pacific Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 78: Asia Pacific Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 79: Asia Pacific Platinum based Cancer Drug Market Forecast (USD Billion), by Others, 2016-2027
Figure 80: Asia Pacific Platinum based Cancer Drug Market Forecast (USD Billion), by China, 2016-2027
Figure 81: Asia Pacific Platinum based Cancer Drug Market Forecast (USD Billion), by India, 2016-2027
Figure 82: Asia Pacific Platinum based Cancer Drug Market Forecast (USD Billion), by Japan, 2016-2027
Figure 83: Asia Pacific Platinum based Cancer Drug Market Forecast (USD Billion), by Australia, 2016-2027
Figure 84: Asia Pacific Platinum based Cancer Drug Market Forecast (USD Billion), by Southeast Asia, 2016-2027
Figure 85: Asia Pacific Platinum based Cancer Drug Market Forecast (USD Billion), by Rest of Asia Pacific, 2016-2027
Figure 86: Middle East & Africa Platinum based Cancer Drug Market Value Share (%), By Segment 1, 2019 & 2027
Figure 87: Middle East & Africa Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 88: Middle East & Africa Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 89: Middle East & Africa Platinum based Cancer Drug Market Value Share (%), By Segment 2, 2019 & 2027
Figure 90: Middle East & Africa Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 91: Middle East & Africa Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 92: Middle East & Africa Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 93: Middle East & Africa Platinum based Cancer Drug Market Forecast (USD Billion), by Others, 2016-2027
Figure 94: Middle East & Africa Platinum based Cancer Drug Market Value Share (%), By Segment 3, 2019 & 2027
Figure 95: Middle East & Africa Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
Figure 96: Middle East & Africa Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
Figure 97: Middle East & Africa Platinum based Cancer Drug Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
Figure 98: Middle East & Africa Platinum based Cancer Drug Market Forecast (USD Billion), by Others, 2016-2027
Figure 99: Middle East & Africa Platinum based Cancer Drug Market Forecast (USD Billion), by GCC, 2016-2027
Figure 100: Middle East & Africa Platinum based Cancer Drug Market Forecast (USD Billion), by South Africa, 2016-2027
Figure 101: Middle East & Africa Platinum based Cancer Drug Market Forecast (USD Billion), by Rest of Middle East & Africa, 2016-2027
List of Tables
Table 1: Global Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
Table 2: Global Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
Table 3: Global Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
Table 4: Global Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Region, 2016-2027
Table 5: North America Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
Table 6: North America Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
Table 7: North America Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
Table 8: North America Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Country, 2016-2027
Table 9: Europe Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
Table 10: Europe Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
Table 11: Europe Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
Table 12: Europe Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Country, 2016-2027
Table 13: Latin America Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
Table 14: Latin America Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
Table 15: Latin America Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
Table 16: Latin America Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Country, 2016-2027
Table 17: Asia Pacific Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
Table 18: Asia Pacific Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
Table 19: Asia Pacific Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
Table 20: Asia Pacific Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Country, 2016-2027
Table 21: Middle East & Africa Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
Table 22: Middle East & Africa Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
Table 23: Middle East & Africa Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
Table 24: Middle East & Africa Platinum based Cancer Drug Market Revenue (USD Billion) Forecast, by Country, 2016-2027
Research Process
Data Library Research are conducted by industry experts who offer insight on
industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager
and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Primary Research
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary Research
Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size Estimation
Both, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
